Ardelyx, Inc.
(NASDAQ : ARDX)

( )
ARDX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
1.31%353.031.2%$871.11m
AMGNAmgen Inc.
-0.53%194.881.2%$564.77m
CELGCelgene Corporation
-0.54%85.231.2%$555.79m
GILDGilead Sciences, Inc.
-0.16%77.260.9%$499.41m
SRPTSarepta Therapeutics, Inc.
-1.97%136.6816.6%$376.94m
VRTXVertex Pharmaceuticals Incorporated
0.40%181.221.9%$331.68m
REGNRegeneron Pharmaceuticals, Inc.
-0.79%364.752.6%$305.25m
ILMNIllumina, Inc.
-1.63%301.993.5%$267.19m
BLUEBluebird Bio, Inc.
-1.83%177.3015.7%$219.07m
NKTRNektar Therapeutics
0.00%47.795.6%$188.00m
ALXNAlexion Pharmaceuticals, Inc.
-0.95%134.582.0%$175.68m
FMIFoundation Medicine, Inc.
0.00%136.708.8%$168.36m
EXASExact Sciences Corporation
1.41%64.6625.4%$159.06m
BMRNBioMarin Pharmaceutical Inc.
-0.85%102.734.4%$138.72m
EXELExelixis, Inc.
-3.61%21.076.4%$137.74m

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicine for the treatment of renal diseases. It also focuses on the development of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.